Kv11.1 Channels in Cardiac Health and Disease: Molecular Insights and Clinical Relevance

Abstract

Kv11.1 (hERG1) channels, encoded by KCNH2, mediate the rapid delayed rectifier potassium current (I_Kr) crucial for cardiac repolarization. Disruptions, via mutations or antiarrhythmic drugs like dofetilide cause severe arrhythmogenic disorders, including Long QT Syndrome Type 2 (LQT2), Brugada Syndrome (BrS), and Torsades de Pointes (TdP). While Kv11.1’s role in channelopathies and drug-induced arrhythmias is established, understanding its complex regulation and therapeutic targeting remains a challenge. This review synthesizes the structural, functional, and regulatory aspects of Kv11.1 channels and their clinical implications. Recent studies using iPSC-derived cardiomyocytes highlight regulation by PI3K/Akt, PKC, and PKA signaling via phosphorylation (Ser283, Ser890) and interactions with proteins like 14-3-3. Beyond electrophysiology, Kv11.1 influences pathological hypertrophy and non-cardiac functions including insulin secretion. Pharmacological efforts focus on activators to shorten action potential duration and suppress TdP, and blockers with overdose risks. Mutation heterogeneity, exemplified by trafficking impairment (G785D) in LQT2 and gain-of-function (R397C) in BrS, complicates precision therapy. Clinically, systematic risk stratification using electrocardiographic parameters and genotype-specific approaches enables personalized management. Beta-blockers remain first-line therapy for LQTS2, while rigorous avoidance of QT-prolonging medications and electrolyte monitoring form the cornerstones of preventive care. Advancing Kv11.1-targeted therapies with approaches like CRISPR-Cas9 and pharmacological chaperones (e.g., lumacaftor) holds promise for personalized treatments, ultimately reducing arrhythmic events and sudden cardiac death.

1. Background

Kv11.1 channels, also known as human Ether-à-go-go-Related Gene 1 (hERG1), belong to the KCNH family of voltage-gated potassium (K⁺) channels. They contribute to the rapid delayed rectifier K⁺ current (I_Kr) in the myocardium, which is essential for shaping the action potential (AP) during ventricular repolarization. This process participates in the duration of the AP and facilitates impulse conduction through the nodes of the cardiac conduction system. Kv11.1 channels play a crucial role in maintaining the normal electrical rhythm in the heart [1]. The current through Kv11.1 channels is distinct from other K⁺ currents, due to its rapid inactivation relative to activation. In various cell types, Kv11.1 channels contribute to maintaining the resting membrane potential and are involved in cellular responses to electrical impulses. It was shown that even small changes in extracellular K⁺ significantly modulate the size of Kv11.1 currents, in part by changing the voltage-dependence of activation and inactivation [2]. Elevated extracellular potassium enhances Kv11.1 channel conductance and accelerates activation, contributing to repolarization dynamics [3]. Conversely, reduced K⁺ impairs channel function, predisposing to arrhythmias due to prolonged repolarization and early afterdepolarizations [4].

Mutations in the KCNH2 gene can affect multiple aspects of channel function, including voltage dependence of inactivation, activation, and overall gating properties. These mutations may shift the voltage dependence of inactivation toward depolarization or hyperpolarization, resulting in either shorter or longer repolarization intervals, respectively, and contributing to altered cardiac electrophysiology [5]. Sanguinetti et al. (2010), have shown that certain mutations in the KCNH2 gene can affect the duration of cardiac repolarization and often lead to one of the most common forms of long QT syndrome, LQT2 [5].

In their tetrameric structure, Kv11.1-subunits consist of six transmembrane segments (Figure 1). The pore forming domain (PD) consists of two segments with pore loops from each subunit arranged symmetrically. Surrounding the pore, are four voltage-sensing domains (VSD), each comprising four transmembrane segments (S1–S4). The fourth segment (S4) contains positively charged residues that respond to changes in membrane voltage, enabling voltage sensitivity by altering their position accordingly. The S4–S5 linker transmits conformational changes from the VSD to the PD to mediate channel gating, traditionally modeled as a mechanical lever [1]; however, functional split-channel constructs reveal that non-covalent interactions suffice, indicating a more complex, modular transduction mechanism [1]. The S4 segment with its hydrophobic residues plays a critical role in the inactivation of Kv11.1 channels [6]. Additionally, specific amino acids (AA), Y652 and F656 located on the S6 segment are responsible for binding channel inhibitors and drugs that target the channel [7,8].

In many species, including humans, Kv11.1 plays a crucial role in regulating cellular excitability in smooth muscle cells of the gastrointestinal tract [9], major artery walls, and uterine myometrium [10]. All of these muscles can display spontaneous phasic contractile activity, which is driven by the generation of APs. These APs are bursts of electrical activity that trigger Ca²⁺ influx, leading to the rhythmic contraction and relaxation characteristic of these smooth muscle tissues [9,10]. Kv11.1 is required for adrenaline release, migration of primary bone marrow tissue cells, proliferation of kidney, liver, lung, lymph node, and pituitary cells, and various blood cell functions such as proliferation, apoptosis, vascular endothelial growth factor (VEGF) secretion, and micro-vesicle release. It also helps the pancreas to secrete insulin [11].

Figure 1. Structure, regulation targets, and mutation sites of the Kv11.1 channel. (a) Schematic of the assembled tetrameric channel viewed from the cytoplasm, showing voltage-sensing domains (VSD, S1–S4) and pore domains (PD, including S5–S6). The triangle marks the approximate drug-binding site within the pore. (b) Top view of the homotetrameric crystal structure (PDB ID: 5VA1); each subunit shown in a distinct color. (c) Single subunit schematic showing transmembrane domains, intracellular N- and C-termini, regulatory phosphorylation/interaction sites (arrows), and positions of selected disease-associated mutations (dots). (Abbreviations: PKA, protein kinase A; PKC, protein kinase C; PKD, protein kinase D; SFKs, Src family kinases; cNBD, cyclic nucleotide-binding domain; Nedd4-2, neural precursor cell expressed developmentally down-regulated protein 4-2; PAS, Per-Arnt-Sim; PH, pore helix). Created in BioRender. Stojchevski, R. (2026) https://BioRender.com/o37g626 (accessed on 12 December 2025) [12]. Structural visualization in (b) was performed using Mol* Viewer (https://molstar.org/viewer/ (accessed on 12 December 2025)).

Figure 1. Structure, regulation targets, and mutation sites of the Kv11.1 channel. (a) Schematic of the assembled tetrameric channel viewed from the cytoplasm, showing voltage-sensing domains (VSD, S1–S4) and pore domains (PD, including S5–S6). The triangle marks the approximate drug-binding site within the pore. (b) Top view of the homotetrameric crystal structure (PDB ID: 5VA1); each subunit shown in a distinct color. (c) Single subunit schematic showing transmembrane domains, intracellular N- and C-termini, regulatory phosphorylation/interaction sites (arrows), and positions of selected disease-associated mutations (dots). (Abbreviations: PKA, protein kinase A; PKC, protein kinase C; PKD, protein kinase D; SFKs, Src family kinases; cNBD, cyclic nucleotide-binding domain; Nedd4-2, neural precursor cell expressed developmentally down-regulated protein 4-2; PAS, Per-Arnt-Sim; PH, pore helix). Created in BioRender. Stojchevski, R. (2026) https://BioRender.com/o37g626 (accessed on 12 December 2025) [12]. Structural visualization in (b) was performed using Mol* Viewer (https://molstar.org/viewer/ (accessed on 12 December 2025)).

The Kv11.1 channel gene (KCNH2) is located on chromosome 7 at the q36.1 region and comprises 15 exons. Exon 1 encodes the 5′ untranslated region (5′ UTR) and the first 26 residues, which are critical for controlling channel deactivation. Exons 2 and 3 encode the Per-Arnt-Sim (PAS) domain, while exon 6 encodes the distal half of the NH₂ cytoplasmic terminus and the first three transmembrane (S1–S3) segments. Exon 7 encodes the S4 segment, which plays a key role in regulating voltage sensitivity [13]. Exons 8, 9, and 10 encode two essential domains: the C-linker and the cyclic nucleotide-binding domain (cNBD). Finally, exons 11–15 encode the distal domain of the COOH terminus. The channel subunits are synthesized in the endoplasmic reticulum (ER), where they assemble into a tetrameric structure. This structure undergoes glycosylation in the Golgi apparatus before being transported to the plasma membrane [13].

Splicing of intron 9 and activation of the distal polyadenylation (polyA) site in exon 15 result in the synthesis of the Kv11.1a isoform, which exhibits normal activity. In contrast, activation of the proximal polyA site in intron 9 produces a C-terminally truncated, nonfunctional isoform known as Kv11.1a-Untranslated Splice Out (Kv11.1a-USO). Hu antigens R and D (HuR and HuD), also referred to as Embryonic Lethal Abnormal Vision-Like 1 and 4 (ELAVL1 and ELAVL4, respectively), regulate the production of these isoforms by inhibiting polyadenylation in intron 9. It was confirmed by Gong et al. (2018) that the proper functioning of this regulator increases Kv11.1a isoform expression and enhances Kv11.1 current [14]. Kv11.1 channels have at least two subunits encoding alternative KCNH2 variants—hERG1a and hERG1b—which differ in their N-terminal domains. In hERG1a, this domain contains PAS, whereas in hERG1b, the N-terminal domain is much shorter and lacks PAS [15].

Kv11.1 channels open at a membrane potential of −50 mV and require −30 mV for half-activation. The conductance of a single channel is approximately 12.4 pS at voltages ranging from −60 to −120 mV, in symmetrical K⁺ concentration of 120 mM. The half-potential for channel inactivation, as a function of voltage, is approximately −85 mV [3,5]. Kv11.1 channels inactivate rapidly in response to rapid depolarization, restricting additional ion movement and leading to a decrease in current at high voltages. This behavior contributes to the characteristic bell-shaped downward slope of the I/V curve. During repolarization, the channels recover from inactivation about 10 times faster than they deactivate, making Kv11.1 channels essential for shaping the current during delayed repolarization in the heart [5]. At positive membrane potentials (MP), Kv11.1 channels exhibit greater inactivation, resulting in a decrease in current as the MP approaches the peak of the action potential (AP). Following the AP peak, the current through Kv11.1 channels increases until the third phase of repolarization [5]. Because these biophysical parameters are sensitive to the expression system, recording temperature, and ionic composition of the experimental solutions, Table 1 summarizes key electrophysiological properties of Kv11.1 channels as reported across major experimental platforms. For example, the half-activation voltage (V½) varies from approximately −15 mV in Xenopus oocytes at room temperature to −18 to −25 mV for native I_Kr in cardiomyocytes at physiological temperature [3,5,13]. Similarly, single-channel conductance values range from approximately 10 to 13 pS depending on ionic conditions and cell type [3,5,13]. These differences reflect both genuine biological variability, such as the presence of auxiliary subunits and the intracellular signaling environment in native cells, and methodological factors including temperature, [K⁺]_o, and the voltage protocol employed. Readers should therefore interpret the specific numeric values presented throughout this review in the context of their respective experimental conditions.

Table 1. Key biophysical properties of Kv11.1 channels across expression systems.

Parameter	Xenopus oocytes	HEK293 Cells	Native Cardiomyocytes (IKr)	References
Activation threshold	~−40 mV (RT)	~−50 mV (35 °C)	~−40 to −50 mV (37 °C)	[3,5,13]
V½ activation	−15.1 mV (RT, 2 mM [K+]o)	−25 to −30 mV (RT); shifts negative at 35 °C	−18 to −25 mV (37 °C, physiological [K+]o)	[3,5,13]
Slope factor (activation)	7–9 mV	7–10 mV	7–8 mV	[5,13]
Single-channel conductance	~10–12 pS (−50 to −110 mV, symm. 100–120 mM K+)	12.4 pS (−60 to −120 mV, symm. 120 mM K+)	Estimated to be substantially lower than heterologous systems; precise values remain uncertain	[3,5,13]
V½ inactivation	−60 to −94 mV (RT) (varies with protocol)	−55 to −85 mV (varies with protocol)	Not fully characterized in human	[3,5,13]
Recovery from inactivation	~10× faster than deactivation			[5,13]
Temperature sensitivity	Q10 activation > Q10 inactivation	Kinetics ~2-fold faster at 35 °C vs. 23 °C	Limited systematic data; recordings typically performed at 35–37 °C	[16,17,18]
[K+]o sensitivity	Conductance increases with [K+]o; activation is insensitive to changes in [K+]o.			[2,3,4,13]

Table 1. Key biophysical properties of Kv11.1 channels across expression systems.

Parameter	Xenopus oocytes	HEK293 Cells	Native Cardiomyocytes (IKr)	References
Activation threshold	~−40 mV (RT)	~−50 mV (35 °C)	~−40 to −50 mV (37 °C)	[3,5,13]
V½ activation	−15.1 mV (RT, 2 mM [K+]o)	−25 to −30 mV (RT); shifts negative at 35 °C	−18 to −25 mV (37 °C, physiological [K+]o)	[3,5,13]
Slope factor (activation)	7–9 mV	7–10 mV	7–8 mV	[5,13]
Single-channel conductance	~10–12 pS (−50 to −110 mV, symm. 100–120 mM K+)	12.4 pS (−60 to −120 mV, symm. 120 mM K+)	Estimated to be substantially lower than heterologous systems; precise values remain uncertain	[3,5,13]
V½ inactivation	−60 to −94 mV (RT) (varies with protocol)	−55 to −85 mV (varies with protocol)	Not fully characterized in human	[3,5,13]
Recovery from inactivation	~10× faster than deactivation			[5,13]
Temperature sensitivity	Q10 activation > Q10 inactivation	Kinetics ~2-fold faster at 35 °C vs. 23 °C	Limited systematic data; recordings typically performed at 35–37 °C	[16,17,18]
[K+]o sensitivity	Conductance increases with [K+]o; activation is insensitive to changes in [K+]o.			[2,3,4,13]

In human embryonic kidney (HEK293) cells, the hERG1b variant (which lacks the PAS domain) is responsible for a twofold acceleration in the activation, deactivation, and recovery from activation of channels composed of hERG1a and hERG1b, compared to channels composed solely of hERG1a. In CMs, suppression of hERG1b prolongs the AP, whereas disabling the PAS domain in hERG1a channels increases the I_Kr current and accelerates cardiac tissue repolarization [14]. The KCNH2 gene encodes the Human Ether-à-go-go-Related Gene 1 non-pore-forming (hERG1NP) polypeptide, which is primarily active in immature cardiac cells. Its main function is to regulate Kv11.1 channels by reducing the surface expression of hERG1a and increasing the inactivation of these channels [15]. Interruptions in the C-terminal regions of the fourth and fifth transmembrane segments (S4 and S5) slow the deactivation of Kv11.1 channels [14].

Regarding pharmacological properties, Kv11.1 agonists exert their effects through four primary mechanisms: (1) reducing the rate of deactivation; (2) attenuating inactivation; (3) enhancing the probability of Kv11.1 channel opening; and (4) shifting the channel’s activation potential to more negative membrane voltages. Notably, most studied agonists simultaneously target multiple mechanisms [19]. Numerous small-molecule activators have been identified that act through various combinations of these four mechanisms, including NS1643 (primarily mechanism 2) [20], RPR260243 (mechanism 1) [21], PD-118057 and its analogs (mechanism 3) [22], ICA-105574 (mechanisms 1–3, with >10-fold I_Kr enhancement) [19], and the natural products Ginsenoside Rg3 (mechanisms 1 and 3) and Mallotoxin (mechanisms 1, 3, and 4); additional compounds are reviewed comprehensively by Sanguinetti (2014) [19]. While most of these remain research tool compounds characterized only in heterologous expression systems, two activators have advanced toward translational application: ICA-105574, which has been shown to restore I_Kr and normalize repolarization in iPSC-CM models of congenital LQTS2 (see Section 3.2), and LUF7244, which selectively enhances I_Kr without affecting other cardiac currents and has demonstrated in vivo suppression of dofetilide-induced TdP in a chronic atrioventricular block dog model (see Section 3.2).

MinK (KCNE1) and MiRP1 (KCNE2) are auxiliary β-subunits with a single TM domain that modulate the function of various voltage-gated potassium channels, including Kv11.1. These β-subunits interact with the pore-forming α-subunits of Kv11.1, influencing key channel properties such as conductance, gating kinetics, and pharmacological sensitivity. Although the precise mechanisms underlying these interactions remain incompletely understood, experimental studies in systems like oocytes and mammalian cells have demonstrated that MinK and MiRP1 significantly alter Kv11.1 channel activity. These modifications suggest a critical role for MinK and MiRP1 in fine-tuning the biophysical behavior of Kv11.1 channels, with potential implications for their physiological function in cardiac repolarization and their involvement in arrhythmias and other pathological conditions [13]. KCNQ1 channels are known to influence Kv11.1 function, and their co-expression in certain cell types can accelerate Kv11.1 deactivation through interactions mediated by the COOH-terminal domain. However, conflicting evidence exists, with some studies reporting that co-expression instead reduces Kv11.1 current. The reasons for these discrepancies remain unclear and warrant further investigation [13]. Kv channel regulatory protein 1 (KCR1), a protein with 12 transmembrane (TM) domains primarily involved in K⁺ channel regulation, interacts with Kv11.1 at the membrane. This interaction reduces the channel’s sensitivity to blockers such as dofetilide, quinidine, and sotalol, thereby modulating its pharmacological properties [13].

Kv11.1 channels also play a critical role in cardiac cell differentiation and recovery following sepsis by forming complexes with integrin β1. This interaction activates focal adhesion kinase (FAK), contributing to downstream signaling. Furthermore, integrin β1 not only activates Kv11.1 channels but also allows Kv11.1 activity to influence signaling pathways that promote integrin receptor activation, highlighting a reciprocal regulatory relationship [23].

Given the critical role of Kv11.1 channels in cardiac repolarization and their systemic significance across various physiological and pathological contexts, it is essential to consolidate and analyze existing knowledge regarding their molecular mechanisms and clinical relevance. Several authoritative reviews have addressed the biophysics and pharmacology of Kv11.1 channels, most notably the comprehensive work by Vandenberg et al. (2012) [13]. Since then, significant advances have reshaped the field: patient-derived iPSC-cardiomyocyte models have enabled functional characterization of specific KCNH2 variants in a human cardiac context; pharmacological chaperones originally developed for cystic fibrosis have been repurposed for trafficking-deficient Kv11.1 mutations; selective channel activators have progressed to in vivo proof-of-concept studies; and the genetic and electrophysiological basis of KCNH2 gain-of-function in Brugada syndrome has been delineated, opening the door to substrate-based interventional strategies. The present review aims to synthesize these developments alongside the established molecular framework, and to bridge the gap between bench-level mechanistic insights and bedside clinical decision-making through an integrated management algorithm (Figure 2) that, to our knowledge, has not been presented in prior reviews of this channel.

This narrative review was based on a structured literature search conducted through PubMed, Scopus, and Web of Science using the search terms “Kv11.1,” “hERG(1),” “KCNH2,” “I_Kr,” “long QT syndrome,” “Brugada syndrome,” and “cardiac repolarization,” combined with terms specific to each section (e.g., “phosphorylation,” “trafficking,” “pharmacological chaperone,” “epicardial ablation,” “drug-induced arrhythmia”). The search encompassed articles published from database inception through February 2026, with no language restrictions. Reference lists of retrieved articles and relevant reviews were screened to identify additional sources. Priority was given to recent peer-reviewed original research, clinical studies, and consensus guidelines.

2. Molecular Regulation of Kv11.1 Channels

2.1. Acute Modulation by Phosphorylation

A number of intracellular signaling pathways regulate Kv11.1 activity mainly through phosphorylation (Table 2 and Figure 1c). Kv11.1 contains four phosphorylation sites for protein kinase A (PKA): Ser283 in the NH₂ terminus and Ser890, Thr895, and Ser1137 in the COOH terminus [24]. Additionally, a single nucleotide polymorphism (SNP), RS1805123, introduces an additional phosphorylation site, K897T [25].

PKA-mediated regulation of Kv11.1 channels is closely associated with β-adrenergic stimulation [26]. Activation of β-adrenergic receptors (βAR) by catecholamines, such as noradrenaline, increases intracellular cAMP levels, leading to PKA activation. This process enhances the phosphorylation of Kv11.1 channels, modulating their kinetics and increasing repolarizing potassium currents [27]. In contrast, parasympathetic activation via acetylcholine counteracts these effects by reducing PKA activity. Therefore, the balance between sympathetic and parasympathetic inputs plays a critical role in the regulation of Kv11.1 channel function. PKA is primarily activated by cyclic adenosine monophosphate (cAMP), whose levels rise in response to βAR stimulation, further emphasizing the interplay between β-adrenergic signaling and Kv11.1 channel regulation [26].

The PKA-mediated regulation of Kv11.1 channels through β-adrenergic stimulation provides the mechanistic basis for beta-blocker efficacy in LQTS2. During catecholamine surges associated with emotional stress or auditory stimuli, β-adrenergic receptor activation normally enhances I_Kr through PKA phosphorylation, facilitating rapid repolarization. In LQTS2 patients with reduced I_Kr reserve, this compensatory mechanism proves insufficient, leading to excessive QT prolongation and arrhythmogenesis. Beta-blockers attenuate this pathway, reducing QT dynamicity and preventing trigger-induced arrhythmias. This mechanism explains the particular efficacy of beta-blockade in LQTS2 compared to other channelopathies and underscores the importance of consistent adherence, especially during high-stress periods.

A-kinase adaptor proteins (AKAP), play a crucial role in mediating PKA phosphorylation of Kv11.1. Huang et al. (2020), demonstrated that Kv11.1 interacts with PKA and AKAP5, localized at the cell membrane, and form intracellular complexes as a result of these interactions [28].

Another group of proteins involved in regulating Kv11.1 are the 14-3-3 proteins, which are highly conserved regulatory molecules (Table 2). The 14-3-3 ε protein binds to PKA-phosphorylated Kv11.1 at both -NH₂ and -COOH sites, stabilizing the PKA-phosphorylated state of the channel. This stabilization provides flexibility in the autonomic control of stress-dependent regulation of cardiac membrane excitability [28,29,30,31].

Another protein kinase that influences Kv11.1 is serine/threonine-specific protein kinase (Akt) or protein kinase B (PKB) (Table 2). Although the regulation of the Kv11.1 channel by Akt in CMs is not extensively documented, insights can be drawn from related studies. Maier et al. (2006) [32] demonstrated that co-expression of Serum- and Glucocorticoid-Regulated Kinase 3 (SGK3), in the phosphatidylinositol 3-kinase (PI3K) regulated signaling pathway [33], along with Kv11.1 channels in Xenopus oocytes, increased both the steady-state current and the abundance of channel proteins at the cell membrane without altering their gating kinetics. Notably, this effect persisted even when SGK phosphorylation sites were mutated, suggesting that SGK3’s impact is independent of direct channel phosphorylation. Similarly, the expression of constitutively active PKB also enhanced Kv11.1 current in HEK293 cells, although it remains unclear whether this effect requires direct phosphorylation of the channel [34].

Table 2. Molecular regulation of Kv11.1 channels.

Category A: Acute Phosphorylation-Based Modulation
Regulator	Sites/Targets	Functional Effect	Clinical Relevance	References
PKA (β-adrenergic/ cAMP)	Ser283 (N-term), Ser890, Thr895, Ser1137 (C-term); SNP K897T adds site	Enhances IKr kinetics and repolarizing current	Mechanistic basis for β-blocker efficacy in LQTS2; stress-triggered arrhythmia	[24,25,26,27,28]
14-3-3 proteins (e.g., ε isoform)	Binds PKA- phosphorylated N- and C-termini; AKAP5 scaffolds complex	Stabilizes phosphorylated state; prolongs autonomic modulation	Sustained βAR-mediated control of repolarization reserve	[28,29,30,31]
PKC (α1-adrenergic/ muscarinic)	N-terminus (residues 1–354); isoforms α and ε	Increases overall Kv11.1 phosphorylation; isoform-specific IKr inhibition via α1A-AR or AT1R	Autonomic modulation of repolarization; potential link to catecholamine-triggered arrhythmia	[35,36,37,38,39]
PKD (α-adreneregic via PKC)	Ser284 (N-terminus)	Downregulates IKr; attenuated by PKC inhibitors	Additional layer of adrenergic IKr modulation	[40]
Akt/PKB (PI3K pathway)	Not determined (independent of direct phosphorylation)	Enhances steady-state IKr and membrane abundance	Potential cardioprotective role via PI3K/Akt signaling	[32,33,34]
PKG (cGMP/ANP-BNP)	hERG1b-containing channels	Inhibits IKr (atrial > ventricular)	IKr suppression in heart failure; chamber-selective effect	[41]
Tyrosine kinases (EGFR/Src)	Tyr475, Tyr611	Reduces IKr amplitude without gating changes	Growth factor signaling modulates repolarization	[42,43]
Category B: Trafficking and degradation
Nedd4-2 (E3 ubiquitin ligase)	C-terminal PY motif; inhibited by PKC phosphorylation	Ubiquitination/ degradation of mature Kv11.1; PKC-dependent phosphorylation elevates surface expression	Upregulated in pathological cardiac hypertrophy; potential antiarrhythmic target	[27,44,45,46,47]
Category C: Environmental modulation
Acidosis	Extracellular pH-sensitive (not intracellular)	Slows activation/ deactivation; reduces IKr	Ischaemia-associated arrhythmogenesis	[48,49,50,51,52]
Temperature	Activation > inactivation sensitivity	Kinetics temperature-dependent (25–37 °C range)	Febrile states may alter repolarization dynamics	[16,17,18]
Oxidative stress/hypoxia	Hsp90 interaction disrupted	Downregulates IKr; induces EADs	Ischaemia/reperfusion-triggered arrhythmias	[53,54]

Table 2. Molecular regulation of Kv11.1 channels.

Category A: Acute Phosphorylation-Based Modulation
Regulator	Sites/Targets	Functional Effect	Clinical Relevance	References
PKA (β-adrenergic/ cAMP)	Ser283 (N-term), Ser890, Thr895, Ser1137 (C-term); SNP K897T adds site	Enhances IKr kinetics and repolarizing current	Mechanistic basis for β-blocker efficacy in LQTS2; stress-triggered arrhythmia	[24,25,26,27,28]
14-3-3 proteins (e.g., ε isoform)	Binds PKA- phosphorylated N- and C-termini; AKAP5 scaffolds complex	Stabilizes phosphorylated state; prolongs autonomic modulation	Sustained βAR-mediated control of repolarization reserve	[28,29,30,31]
PKC (α1-adrenergic/ muscarinic)	N-terminus (residues 1–354); isoforms α and ε	Increases overall Kv11.1 phosphorylation; isoform-specific IKr inhibition via α1A-AR or AT1R	Autonomic modulation of repolarization; potential link to catecholamine-triggered arrhythmia	[35,36,37,38,39]
PKD (α-adreneregic via PKC)	Ser284 (N-terminus)	Downregulates IKr; attenuated by PKC inhibitors	Additional layer of adrenergic IKr modulation	[40]
Akt/PKB (PI3K pathway)	Not determined (independent of direct phosphorylation)	Enhances steady-state IKr and membrane abundance	Potential cardioprotective role via PI3K/Akt signaling	[32,33,34]
PKG (cGMP/ANP-BNP)	hERG1b-containing channels	Inhibits IKr (atrial > ventricular)	IKr suppression in heart failure; chamber-selective effect	[41]
Tyrosine kinases (EGFR/Src)	Tyr475, Tyr611	Reduces IKr amplitude without gating changes	Growth factor signaling modulates repolarization	[42,43]
Category B: Trafficking and degradation
Nedd4-2 (E3 ubiquitin ligase)	C-terminal PY motif; inhibited by PKC phosphorylation	Ubiquitination/ degradation of mature Kv11.1; PKC-dependent phosphorylation elevates surface expression	Upregulated in pathological cardiac hypertrophy; potential antiarrhythmic target	[27,44,45,46,47]
Category C: Environmental modulation
Acidosis	Extracellular pH-sensitive (not intracellular)	Slows activation/ deactivation; reduces IKr	Ischaemia-associated arrhythmogenesis	[48,49,50,51,52]
Temperature	Activation > inactivation sensitivity	Kinetics temperature-dependent (25–37 °C range)	Febrile states may alter repolarization dynamics	[16,17,18]
Oxidative stress/hypoxia	Hsp90 interaction disrupted	Downregulates IKr; induces EADs	Ischaemia/reperfusion-triggered arrhythmias	[53,54]

Protein kinase C (PKC) has been shown to regulate the activity of Kv11.1 channels (Table 2). Thomas et al. (2003), identified 18 potential phosphorylation sites for PKC in Kv11.1, including various serine and threonine residues [35]. However, mutating these sites to alanine did not abolish PKC’s acute regulatory effect, suggesting that direct phosphorylation of these residues might not be essential for PKC-mediated modulation. Cockerill et al. (2007) further confirmed that Kv11.1 channels, with all 18 identified mutated PKC phosphorylation sites, remained responsive to PKC regulation [36]. Their findings demonstrated that PKC activation increased the overall phosphorylation levels of Kv11.1. Deleting the -NH₂ terminus (amino acids 2–354) abolished both, the PKC-stimulated increase in phosphoprotein levels and the acute functional effects on Kv11.1, indicating that residues in the -NH₂ terminus may serve as direct phosphorylation targets for PKC. In the same direction, subsequent study demonstrated that PKC directly phosphorylates the -NH₂ terminus of Kv11.1 in HEK293 cells and feline CMs following α1-adrenergic receptor (α1-AR) activation [37]. To explore the differential effects of PKC isoforms, Radresa et al. (2014), used peptide-mimetic and synthetic modulators targeting PKC [38]. Their study elucidated the critical role of PKCε in regulating Kv11.1 channel activity and highlighted the varying impacts of different PKC subtypes. Liu et al. (2017), further demonstrated that inhibition of I_Kr was mediated by the PKCα and PKCε isoforms, via distinct molecular mechanisms, following activation of α1A-adrenergic receptors or Angiotensin II Type 1 receptors (AT1), respectively [39]. In vivo and in vitro mass spectrometry findings, combined with functional analysis of wild type (WT) and mutant Kv11.1 channels, revealed that different stimuli induce protein kinase D (PKD), activation through the α-adrenergic pathway (Table 2). This activation could be attenuated by PKC inhibition. PKD, practically contributes to Kv11.1 regulation by targeting S284 in the N-terminus of the channel [40].

Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), released from the atria in response to stretch or dilation, are elevated during heart failure. ANP exerts its effects through the cyclic guanosine monophosphate (cGMP) signaling pathway, which influences Kv11.1 channels, particularly those containing the hERG1b isoform (Table 2). In various cell lines, cGMP significantly inhibits Kv11.1 channels composed of hERG1b or hERG1a/1b subunits in a protein kinase G (PKG)-dependent manner. In mouse hearts, cGMP suppresses I_Kr in atrial myocytes but not in ventricular myocytes [41].

Tyrosine kinases also play a role in modulating Kv11.1 channels. Zhang et al. (2008) [42], observed a reduction in Kv11.1 current amplitude following inhibition of the Epidermal Growth Factor Receptor (EGFR) kinase and non-receptor tyrosine (Src) family kinases. This effect was attributed to decreased phosphorylation of Tyr475 and/or Tyr611 [42]. Building on these findings, subsequent studies demonstrated that the tyrosine kinase inhibitor 4-Amino-1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d] pyrimidine (PP1), and the selective Src inhibitory peptide Src40-58 reduced Kv11.1 current amplitude, without affecting the channel’s voltage dependence or kinetics [43].

2.2. Channel Trafficking and Degradation

Interestingly, PKC activation can enhance Kv11.1 channel expression and function. The E3 ubiquitin ligase, Neural precursor cell expressed, developmentally downregulated 4-2 (Nedd4-2), interacts with Kv11.1 through a proline (P) and tyrosine (Y) [44] (PY) motif located in its C-terminus, promoting degradation of mature Kv11.1 proteins during channel trafficking. However, muscarinic receptor activation, increases Kv11.1 channel expression by phosphorylating Nedd4-2 via a PKC regulated pathway [27,45,46]. Subsequent research confirmed that PKC phosphorylation inhibits Nedd4-2, leading to elevated Kv11.1 protein levels [47]. These findings underscore the role of Nedd4-2 as a critical regulator of I_Kr and suggest that pharmacological suppression of Nedd4-2 may offer a novel antiarrhythmic therapy for pathological cardiac hypertrophy (pCH) [47].

2.3. Environmental Modulation

Acidosis affects I_Kr by reducing Kv11.1 current under acidic conditions [48,49], whereas intracellular pH changes do not appear to affect these currents (Table 2) [48]. Voltage-clamp fluorometry studies have shown that extracellular acidosis slows the return of the voltage sensor during deactivation, accelerates deactivation rates [50,51], and slows channel activation [1,49,52].

Temperature significantly influences Kv11.1 channels (Table 2). Like other K⁺ channels, Kv11.1 channel kinetics exhibit temperature-sensitivity [16,17]. Notably, studies have shown that Kv11.1 activation is considerably more temperature-sensitive than inactivation [16]. Lei et al. (2019) quantified this difference using mathematical models and experimental data obtained at five distinct temperatures ranging from 25 to 37 °C [18].

Oxidative stress is another key factor that significantly affects Kv11.1 channels (Table 2). It is known to induce early afterdepolarizations (EADs). Since Kv11.1 channels play a critical role in suppressing EADs, any reduction in I_Kr caused by oxidative stress increases the probability of EAD occurrence [53]. Chronic hypoxia has been shown to reduce Kv11.1 channel protein synthesis by disrupting the interaction between Kv11.1 and its maturation chaperone, Heat Shock Protein 90 (Hsp90) [54]. These findings underscore the intricate interplay between cellular and environmental factors in Kv11.1 channel regulation.

A deeper understanding of these mechanisms holds significant therapeutic potential for managing cardiac arrhythmias. Targeted interventions could focus on modulating specific phosphorylation sites, enhancing or inhibiting channel trafficking, or mitigating the effects of external stressors such as oxidative damage. Additionally, uncovering the differential effects of regulatory kinases and interacting proteins opens the door to precision therapies designed to restore normal Kv11.1 channel activity. By applying these insights, antiarrhythmic strategies can be refined, offering improved outcomes for patients with conditions associated with Kv11.1 dysfunction.

3. Kv11.1 Channels in Diseased Cardiomyocytes

The study of Kv11.1 channels in disease has relied on a hierarchy of preclinical models, each offering distinct advantages and limitations. Heterologous expression systems, principally Xenopus oocytes, HEK293 cells, and CHO cells, enable controlled biophysical characterization of individual mutations and drug interactions, but lack the native cardiac cellular environment (see Table 1 for system-dependent variability in biophysical parameters). Patient-derived iPSC-CMs have substantially advanced the field by providing a human cardiac context for functional studies, enabling assessment of mutation-specific effects on action potential morphology, calcium handling, and drug responses in a genetically relevant background (see Section 3.1). Multicellular preparations, including 3D tissue-on-a-chip models and cultured cell monolayers, capture aspects of cell–cell coupling and tissue-level electrophysiology that isolated cells cannot (see Section 3.1). Finally, animal models, such as the chronic atrioventricular block dog model used to evaluate LUF7244 (see Section 3.2), provide in vivo pharmacokinetic and arrhythmia suppression data essential for translational assessment. The findings discussed in the following sections should be interpreted with awareness of the experimental platform employed, as model selection influences both the observed phenotype and the clinical extrapolability of the results.

3.1. Inherited Channelopathies

The study by Fukumoto et al. (2018) [55], has shown that missense mutations in the KCNH2 gene, which encodes the Kv11.1 channel, cause LQTS2 primarily by disrupting the intracellular transport of Kv11.1 (Table 3). The same study examined the functional changes induced by two novel KCNH2 missense mutations [55]. Specifically, by transfecting Chinese hamster ovary (CHO) cells with WT and mutant KCNH2 plasmids and conducting patch-clamp recordings they have found that both G785D and T826I mutant channels were nonfunctional in the homozygous state (Table 3).

In the heterozygous state, these mutations caused a 50% reduction in current density compared to WT Kv11.1 channels [55]. Immunostaining and confocal microscopy of HEK cells expressing WT and mutant Kv11.1 channels revealed that both mutations disrupted proper intracellular transport. The mutant channels were predominantly retained in the endoplasmic reticulum (ER), indicating a trafficking deficiency [55]. Culturing cells at 30 °C partially restored the plasma membrane expression of the Kv11.1-T826I mutant but had no effect on the G785D mutant (Table 3). Furthermore, exposure to Kv11.1 channel blockers E-4031 and dofetilide failed to induce measurable currents in either mutant channel, suggesting that these pharmacological agents were ineffective in preserving mutant channel function [55]. The differential response to low-temperature incubation between the two mutants highlights the potential for targeted therapeutic strategies to correct specific trafficking defects.

Long QT Syndrome Type 2 (LQTS2) is caused by pathogenic variants in the KCNH2 gene, which encodes the α-subunit of the Kv11.1 channel, a critical component of the rapid delayed rectifier potassium current [7] (Table 3). In a recent study, an induced pluripotent stem cell (iPSC) line carrying the KCNH2 c.2464G>A (p.Val822Met) pathogenic variant, was developed using the Sendai virus reprogramming method, derived from a patient with LQTS2. CMs differentiated from these iPSCs exhibited decreased levels of functional Kv11.1 channels at the plasma membrane, resulting in prolonged AP repolarization and contributing to arrhythmias [56]. The disruption of Kv11.1 trafficking is a key contributor to congenital forms of long QT syndrome, while in acquired forms, most torsadogenic drugs prolong the QT interval by directly blocking Kv11.1 currents through binding to the channel’s inner cavity [57]. Mutations in the KCNH2 gene, such as the R56Q+/− variant, impair protein trafficking, reduce Kv11.1 currents, prolong AP duration, and increase the risk of arrhythmias [58]. Advanced technologies, including 3D tissue-on-a-chip models, are now being employed to study the pathophysiology of LQTS2 and evaluate potential therapeutic interventions [59]. These innovative approaches highlight the central role of Kv11.1 trafficking defects in LQTS2 pathology, and offer promising avenues for developing targeted therapies. In Brugada Syndrome (BrS), mutations in genes other than SCN5A remain less well understood, with SCN5A being the most studied gene associated with the condition (Table 3). A study by Wang et al. (2014) identified four KCNH2 mutations—T152I, R164C, W927G, and R1135H—in a cohort of 236 patients with BrS or Br-like ECG patterns [60]. Among the mutation carriers, three had corrected QT intervals shorter than 360 milliseconds, and one experienced ventricular fibrillation. Patch-clamp analyses revealed that three mutations (R164C, W927G, and R1135H) significantly increased I_Kr densities, suggesting a gain-of-function effect on the Kv11.1 potassium channel. Additionally, the T152I, R164C, and W927G mutations caused a negative shift in voltage-dependent activation curves, while the R1135H mutation prolonged deactivation time constants. These findings indicate distinct biophysical changes in Kv11.1 channel gating caused by these mutations [60].

Table 3. Kv11.1 channels in diseased CMs (inherited channelopathies). (Selected mutation sites are indicated in Figure 1c).

Mutation/ Condition	Mechanism/Effect	References
LQT2 (Trafficking Defects)	G785D/T826I: ER retention, 50% IKr reduction (heterozygous); nonfunctional homozygous; low-temp rescue partial for T826I only. Val822Met (c.2464G>A): ↓ Plasma membrane Kv11.1, prolonged AP/FPDc. R56Q+/−: Impaired trafficking, ↓ IKr, prolonged APD, ↑ Arrhythmia risk.	[55,56,58]
BrS (Gain-of-Function)	T152I/R164C/W927G/R1135H: ↑ IKr density (3/4 mutations), negative V_act shift (3/4), prolonged deactivation (R1135H); short QTc, phase-2 reentry substrate. R397C (c.1189C>T): No Δ IKr density; ↑ Activation, ↓ Inactivation, window current ↑.	[60,61]
General LQT2 Insights	3D tissue-on-a-chip models reveal trafficking defects as core pathology; drugs bind the inner cavity in acquired forms.	[57,59]

↓, decreased; ↑, increased; Δ, change.

Table 3. Kv11.1 channels in diseased CMs (inherited channelopathies). (Selected mutation sites are indicated in Figure 1c).

Mutation/ Condition	Mechanism/Effect	References
LQT2 (Trafficking Defects)	G785D/T826I: ER retention, 50% IKr reduction (heterozygous); nonfunctional homozygous; low-temp rescue partial for T826I only. Val822Met (c.2464G>A): ↓ Plasma membrane Kv11.1, prolonged AP/FPDc. R56Q+/−: Impaired trafficking, ↓ IKr, prolonged APD, ↑ Arrhythmia risk.	[55,56,58]
BrS (Gain-of-Function)	T152I/R164C/W927G/R1135H: ↑ IKr density (3/4 mutations), negative V_act shift (3/4), prolonged deactivation (R1135H); short QTc, phase-2 reentry substrate. R397C (c.1189C>T): No Δ IKr density; ↑ Activation, ↓ Inactivation, window current ↑.	[60,61]
General LQT2 Insights	3D tissue-on-a-chip models reveal trafficking defects as core pathology; drugs bind the inner cavity in acquired forms.	[57,59]

↓, decreased; ↑, increased; Δ, change.

Mechanistically, gain-of-function mutations in the Kv11.1 channel contribute to BrS by increasing I_Kr, leading to excessive K⁺ efflux during the plateau phase of the cardiac AP. This results in a shortened AP duration and a reduced refractory period, particularly in the right ventricular epicardium. The consequent transmural dispersion of repolarization creates a substrate for phase 2 reentry, a hallmark of BrS, which significantly elevates the risk of ventricular fibrillation and sudden cardiac death [60]. The same study identified 20 SCN5A and 5 CACNA1C mutation carriers, highlighting distinct differences in ECG features among these groups. While KCNH2 mutation carriers were associated with shorter QTc intervals, SCN5A mutation carriers exhibited prolonged QRS durations. These findings suggest that KCNH2 mutations exert gain-of-function effects on I_Kr channels, contributing to the unique ECG characteristics observed in BrS patients with these mutations [60]. These insights enhance our understanding of BrS genetics and emphasize the importance of further investigating the pathogenic mechanisms of KCNH2 mutations in BrS.

A novel genetic variant, c.1189C>T (p.R397C), was identified in the KCNH2 gene of an asymptomatic male proband diagnosed with BrS and mild QTc shortening [61]. This variant is significant as it may influence the I_Kr current, representing a rare, non-SCN5A-related form of BrS. Functional characterization using patch-clamp analysis revealed that the R397C mutation does not alter I_Kr current density. However, it significantly enhances channel activation and reduces inactivation of Kv11.1 channels, resulting in an increased window current, indicative of a gain-of-function effect [61] (Table 3). These findings highlight the expanding genetic spectrum of BrS and provide valuable insights into the potential mechanistic underpinnings of this condition.

3.2. Acquired Channelopathies and Emerging Therapeutic Strategies

In addition to disease-induced downregulation or trafficking defects that resemble loss-of-function mutations observed in congenital LQT2, acquired Kv11.1 channelopathies are primarily caused by pharmacological blockade of the channel pore, which results in prolonged repolarization and torsades de pointes (TdP). As a result, therapeutic approaches like channel activators and pharmacological chaperones that were first created for congenital Kv11.1 mutations have been repurposed and proven effective in acquired settings. The following paragraphs illustrate this continuum, moving from historical recognition of drug-induced TdP to modern activators that rescue both inherited and acquired Kv11.1 dysfunction.

In 1966, Dessertenne documented a case involving an 80-year-old woman with complete atrioventricular block, a prolonged QT interval, and a distinctive form of polymorphic ventricular tachycardia later termed “torsades de pointes” (TdP) [62]. This report marked the first description of TdP, which was subsequently recognized as a hallmark symptom of congenital long QT syndrome (cLQTS) [63].

In a human iPSC-CM (hiPSC-CM) model of cLQTS2 with the expression-defective Kv11.1 mutant A422T, cardiac repolarization was significantly prolonged. This was demonstrated by extended Ca²⁺ transient durations in isolated cells and prolonged rate-corrected field potential durations (FPDc) in cultured cell monolayers [64]. Treatment with the Kv11.1 channel activator ICA-105574 reversed these repolarization abnormalities in a concentration-dependent manner. However, at higher concentrations, ICA-105574 caused FPDc shortening, probably due to a temporal redistribution of peak I_Kr to an earlier point in the plateau phase of the AP, leading to early repolarization [64]. These findings highlight the potential therapeutic benefits of ICA-105574 in cLQTS2 while emphasizing the importance of avoiding overcorrection with excessive dosing.

2-[4-(3-Chlorobenzoyl) phenoxy]-N-3-pyridinyl-acetamide (LUF7244), a selective Kv11.1 channel activator, enhances I_Kv11.1 by inhibiting its inactivation [65]. In vitro studies demonstrated that LUF7244 specifically increased I_Kr without affecting other cardiac ion currents, including I_KIR2.1, I_Nav1.5, I_CaL, or I_Ks. This led to a doubling of I_Kr and a reduction in AP duration by approximately 50% in human and canine CMs, while also effectively suppressing dofetilide-induced EADs [65]. In dogs with sinus rhythm, LUF7244 did not exhibit proarrhythmic effects and caused a modest, non-significant reduction in QTc duration (−6.8%). In a model of chronic atrioventricular block, LUF7244 prevented dofetilide-induced TdP in 5 of 7 animals, despite not fully normalizing the QTc interval. Pharmacokinetic analysis revealed peak plasma concentrations of LUF7244 to be 1.75 ± 0.80 μM during sinus rhythm and 2.34 ± 1.57 μM in animals with chronic atrioventricular block [65]. These findings suggest that LUF7244 is a promising therapeutic agent for suppressing TdP by selectively enhancing I_Kr, without significant proarrhythmic risks or off-target effects (Table 4).

Table 4. Kv11.1 channels in diseased cardiomyocytes (acquired channelopathies and therapeutics).

Agent/ Condition	Mechanism/Effect	References
Activators (Anti-TdP)	ICA-105574: Restores IKr in heterozygous mutants; reverses prolonged Ca2+ transients/FPDc in A422T iPSC-CMs; risk of overcorrection at high doses (early repolarization). LUF7244: Inhibits inactivation, doubles IKr, shortens APD 50%; suppresses dofetilide-EADs/TdP in dog AV-block model (no pro-arrhythmia).	[64,65]
Drug-Induced aLQTS/TdP	General: Blockers (e.g., dofetilide) prolong QT via inner cavity binding; H2O molecules minimally impact 3D QSAR predictions. Loperamide (overdose): Blocks Kv11.1 + Nav1.5; QTc prolongation, QRS widening, TdP risk. hERG1a/1b subunits: Alter drug sensitivity, temperature-dependence affects block kinetics.	[13,66,67,68,69]
Trafficking Rescue (LQT2 Mutations)	Lumacaftor (chaperone): Restores G604S/N633S/R685P trafficking; paradoxical APD90 prolongation in G604S (dominant-negative). Splice mutation (IVS9-2delA): Shifts to nonfunctional Kv11.1a-USO isoform.	[70,71]
Pathological Downregulation	pCH: ↓ Mature/immature Kv11.1 protein (post-transcriptional); KCNQ1/KCNE1 unaffected. Nedd4-2 upregulation increases channel degradation.	[47]

↓, decreased.

Table 4. Kv11.1 channels in diseased cardiomyocytes (acquired channelopathies and therapeutics).

Agent/ Condition	Mechanism/Effect	References
Activators (Anti-TdP)	ICA-105574: Restores IKr in heterozygous mutants; reverses prolonged Ca2+ transients/FPDc in A422T iPSC-CMs; risk of overcorrection at high doses (early repolarization). LUF7244: Inhibits inactivation, doubles IKr, shortens APD 50%; suppresses dofetilide-EADs/TdP in dog AV-block model (no pro-arrhythmia).	[64,65]
Drug-Induced aLQTS/TdP	General: Blockers (e.g., dofetilide) prolong QT via inner cavity binding; H2O molecules minimally impact 3D QSAR predictions. Loperamide (overdose): Blocks Kv11.1 + Nav1.5; QTc prolongation, QRS widening, TdP risk. hERG1a/1b subunits: Alter drug sensitivity, temperature-dependence affects block kinetics.	[13,66,67,68,69]
Trafficking Rescue (LQT2 Mutations)	Lumacaftor (chaperone): Restores G604S/N633S/R685P trafficking; paradoxical APD90 prolongation in G604S (dominant-negative). Splice mutation (IVS9-2delA): Shifts to nonfunctional Kv11.1a-USO isoform.	[70,71]
Pathological Downregulation	pCH: ↓ Mature/immature Kv11.1 protein (post-transcriptional); KCNQ1/KCNE1 unaffected. Nedd4-2 upregulation increases channel degradation.	[47]

↓, decreased.

The inhibition of Kv11.1 channels by drugs has been linked to acquired long QT syndrome (aLQTS) and fatal arrhythmias, leading to the withdrawal of several marketed drugs (Table 4). This has driven significant interest in developing more accurate predictive tests for Kv11.1 channel blockers [13]. The drug-binding pocket of Kv11.1 channels, located below the selectivity filter, typically contains K⁺ ions and H₂O molecules [13]. In the study by Munawar et al. (2019), the hypothesis that H₂O molecules influence drug binding was tested, and 3D Quantitative Structure–Activity Relationship (3D QSAR) models were created using alignment-independent descriptors (GRIND) based on docked ligands in open and closed Kv11.1 conformations, both with and without H₂O molecules [66]. The interactions were summarized using the protein-ligand interaction fingerprint (PLIF) approach. The results showed that all models exhibited similar 3D binding characteristics for Kv11.1, with only minor deviations (~0.4 Å) observed in key interaction hotspots between solvated and non-solvated models [66]. However, these conformational differences did not significantly affect model performance or predictive accuracy, suggesting that H₂O molecules have a limited impact on drug-binding predictions for Kv11.1 channels. The model with the best statistical performance was derived from a cryo-EM structure of the Kv11.1 channel in an open state without H₂O, achieving the highest R² values of 0.58 and 0.51 for the internal and external validation sets, respectively. These findings indicate that including H₂O molecules during docking has a minimal effect on channel conformations and does not significantly influence the predictive accuracy of the 3D QSAR models. Dynamic models of Kv11.1 channels, as described by Pearlstein et al. (2016), highlight the complex interplay between channel–drug binding kinetics and channel gating [57]. Incorporating these dynamics into predictive models provides deeper insights into drug-channel interactions, paving the way for safer therapeutic development and reducing the risk of QT interval prolongation.

Numerous studies have shown that the drug sensitivity of Kv11.1 channels is influenced by various factors including subunit composition and temperature. For example, the presence of hERG1a and hERG1b subunits can significantly modify the channel’s pharmacological response affecting both efficacy and safety profiles of therapeutic agents [67]. Loperamide, a commonly used antidiarrheal medication, has been identified as an inhibitor of Kv11.1 channels, resulting in prolonged cardiac repolarization, QTc interval extension, and an increased risk of TdP. Moreover, loperamide also inhibits Nav1.5 channels, further disrupting cardiac electrical conduction and contributing to QRS interval widening [68]. The combined effects of loperamide on Kv11.1 and Nav1.5 channels highlight serious safety concerns, particularly in cases of overdose or misuse. These adverse outcomes, including QTc prolongation, TdP, and other ECG abnormalities, emphasize the need for cautious administration and vigilant monitoring of loperamide, especially at doses exceeding therapeutic recommendations [69].

Immunoblotting analyses have demonstrated a significant reduction in both the mature and immature forms of the Kv11.1 protein in pCH tissue. In contrast, the expression levels of KCNQ1 and its auxiliary subunit KCNE1 remain unaffected. Notably, mRNA levels of KCNH2 are similar between pCH and control tissues, whereas KCNQ1 mRNA levels are elevated in pCH. These findings suggest that the downregulation of Kv11.1 in pCH is driven by post-transcriptional mechanisms [47].

In Long QT Syndrome Type 2 (LQT2), specific Kv11.1 (KCNH2) mutations result in trafficking defects that hinder the proper localization of Kv11.1 channels to the cell membrane. Studies using iPSC-CMs have identified three such mutations: G604S, N633S, and R685P. Treatment with lumacaftor, a chemical chaperone, successfully restored channel trafficking for all three mutations (Table 4). However, in the KCNH2-G604S mutation, lumacaftor paradoxically prolonged the APD at 90% repolarization (APD90), probably due to enhanced trafficking of mutant channels exacerbating dominant-negative effects [71].

Certain mutations lead to the retention of Kv11.1 channels within the ER’s quality control compartments. Confocal imaging enables the detection of mutation-specific differences in the distribution of trafficking-deficient Kv11.1 protein, providing insights into distinct mechanisms governing protein trafficking. A splice site mutation in KCNH2(IVS9-2delA) has been identified [70]. This mutation disrupts normal splicing, shifting expression from the functional Kv11.1a isoform to the nonfunctional Kv11.1a-USO isoform, thereby compromising normal channel function. These findings underscore the intricate regulation of Kv11.1 channels and emphasize the need for mutation-specific therapeutic strategies in LQT2 management.

4. Clinical Management and Practical Considerations

The translation of molecular insights into clinical practice requires systematic approaches to risk assessment, diagnosis, and therapeutic intervention. This section synthesizes evidence-based guidance for clinicians managing patients with Kv11.1 channelopathies and those prescribing medications with potential Kv11.1 channel interactions, while highlighting areas where current evidence remains incomplete.

4.1. Risk Stratification in LQTS2 Patients

Long QT Syndrome Type 2 accounts for approximately 30% of genetically confirmed LQTS cases, exhibiting distinct clinical features compared to other LQTS subtypes [72]. The corrected QT interval (QTc), calculated using the Bazett formula, serves as the primary diagnostic parameter, with QTc values exceeding 470 ms in males and 480 ms in females raising clinical suspicion [73,74]. However, a fundamental diagnostic challenge emerges from the considerable overlap between affected and unaffected individuals: approximately 25–40% of genotype-positive LQTS2 patients exhibit QTc values within the normal range, a phenomenon termed “concealed LQTS” [75,76]. This observation underscores that QTc prolongation alone possesses insufficient sensitivity for ruling out disease.

The Schwartz score addresses this limitation by integrating QTc duration with T-wave morphology, clinical history, and family history into a structured diagnostic probability assessment [77,78,79]. Scores ≥ 3.5 indicate a high probability of LQTS, while intermediate scores (1.5–3.0) warrant further evaluation, including consideration of genetic testing to establish or exclude the diagnosis [80]. Notably, LQTS2 patients frequently exhibit characteristic bifid or notched T-waves, particularly in precordial leads V2–V4, a morphological pattern that aids genotype differentiation [81]. Figure 2 presents a clinical decision algorithm integrating these elements for systematic management of patients with suspected or confirmed Kv11.1 channelopathies. This algorithm could be referenced when evaluating newly diagnosed patients (Section 4.1), determining therapeutic interventions (Section 4.4), and managing special populations (Section 4.5).

Genotype-phenotype correlations significantly refine risk stratification beyond electrocardiographic parameters. Mutations localized to the pore region of Kv11.1 channels confer substantially higher arrhythmic risk compared to those in N- or C-terminal domains [82,83,84]. Furthermore, mutations exerting dominant-negative effects through disruption of channel trafficking demonstrate more severe phenotypes than those producing haploinsufficiency alone [85,86]. This mechanistic distinction carries therapeutic implications, as dominant-negative mutations may respond differently to pharmacological chaperone therapy (discussed in Section 4.4). Sex-based differences in arrhythmic risk demonstrate age-dependent patterns that inform surveillance strategies. Female LQTS2 patients experience increased cardiac events during the postpartum period and throughout adulthood, whereas male patients face elevated risk during childhood and adolescence [87,88]. These observations likely reflect sex hormone modulation of cardiac repolarization, with testosterone exerting protective effects through enhanced I_Kr current density.

Trigger identification constitutes a critical component of risk assessment distinguishing LQTS2 from other subtypes. Unlike LQTS1, where exercise and swimming predominate as triggers, LQTS2 patients experience cardiac events primarily during emotional stress, auditory stimuli (alarm clocks, telephones), and postpartum periods [89,90]. The “auditory trigger” phenomenon, occurring in approximately 50% of documented cardiac events, appears specific to LQTS2 and reflects the particular vulnerability of I_Kr-dependent repolarization to sudden sympathetic activation. Recognition of these genotype-specific triggers enables targeted patient counseling and environmental modification.

4.2. Drug Safety in Clinical Practice

Drug-induced QT prolongation represents a leading cause of acquired channelopathies, having prompted multiple market withdrawals and FDA black box warnings [91,92]. The underlying molecular basis, i.e., promiscuous drug binding within large hydrophobic pockets of the Kv11.1 channel cavity, enables interactions with structurally diverse compounds across therapeutic classes [93,94]. More than 200 marketed medications demonstrate Kv11.1 channel blocking properties, necessitating systematic screening approaches. Importantly, Kv11.1 sensitivity to pharmacological blockade varies with subunit composition. Heteromeric channels comprising both hERG1a and hERG1b subunits exhibit differential drug sensitivity compared to homomeric assemblies, affecting both efficacy and safety profiles [67]. This molecular heterogeneity may partially explain the substantial interindividual variability observed in drug-induced QT prolongation and has prompted the incorporation of heteromeric channel assays into preclinical screening paradigms.

High-risk medications requiring avoidance in patients with known or suspected LQTS2 encompass Class IA and Class III antiarrhythmics (quinidine, procainamide, sotalol, dofetilide), macrolide antibiotics (erythromycin, clarithromycin, azithromycin), fluoroquinolones (moxifloxacin, levofloxacin), antipsychotics (haloperidol, droperidol, ziprasidone, quetiapine), and antiemetics (ondansetron, domperidone) [95,96]. The CredibleMeds database (www.crediblemeds.org (accessed on 20 December 2025)) provides regularly updated risk categorization based on evidence quality, stratifying medications into known, possible, and conditional TdP risk categories.

Beyond prescription medications, over-the-counter agents warrant clinical attention. Loperamide exemplifies this concern: at therapeutic doses, minimal systemic absorption occurs, but misuse or overdose, as increasingly recognized in opioid use disorder, achieves cardiotoxic plasma concentrations [68,69]. Mechanistically, loperamide produces dual cardiotoxicity through combined Kv11.1 and Nav1.5 blockade, manifesting as QTc prolongation, QRS widening, and elevated TdP risk [69]. Clinicians evaluating unexplained QT prolongation should consider supratherapeutic loperamide use, particularly in populations with substance use disorders.

Pre-prescription screening should incorporate baseline ECG assessment with attention to QTc duration, T-wave morphology, and U-wave presence [95,97]. Comprehensive electrolyte panels measuring potassium, magnesium, and calcium require correction prior to initiating QT-prolonging therapy, as hypokalemia and hypomagnesemia substantially potentiate drug-induced repolarization abnormalities [2,97]. Family history screening for unexplained syncope, seizures, or sudden cardiac death identifies individuals with potential genetic predisposition requiring enhanced surveillance.

Drug–drug interactions amplify Kv11.1 blocking effects through pharmacokinetic mechanisms. CYP3A4 inhibitors, including azole antifungals (ketoconazole, itraconazole), protease inhibitors (ritonavir, indinavir), and macrolide antibiotics, elevate plasma concentrations of Kv11.1 blockers metabolized through this pathway, while P-glycoprotein inhibition enhances tissue accumulation [98,99]. Vigilance regarding these interactions proves particularly important in elderly populations, where polypharmacy prevalence compounds risk.

For patients requiring unavoidable QT-prolonging medications, risk mitigation strategies include selecting the shortest effective treatment duration, utilizing the lowest effective dose, aggressively correcting electrolyte abnormalities, and implementing serial ECG monitoring [100,101,102]. ECG assessment should occur at baseline, following dose escalation, at steady-state (typically 3–5 days post-initiation), and after adding potentially interacting medications. QTc increases exceeding 60 ms from baseline or absolute values exceeding 500 ms warrant consideration of alternative therapies.

4.3. Patient Monitoring Strategies

Systematic surveillance protocols optimize outcomes in patients with confirmed or suspected Kv11.1 channelopathies. Initial diagnostic evaluation should encompass 12-lead ECG, comprehensive personal and family history extending through at least three generations, and exercise stress testing to evaluate QT adaptation during recovery phases [73]. Holter monitoring identifies nocturnal arrhythmias and assesses heart rate variability, while genetic testing confirms diagnosis and enables cascade screening of family members.

For genotype-positive LQTS2 patients, annual clinical evaluation, including history, physical examination, and ECG monitoring represents the minimum recommended surveillance [73]. Patients experiencing syncope, presyncope, palpitations, or documented arrhythmias require intensified monitoring, potentially including event recorders or insertable cardiac monitors. Adolescents and young adults transitioning between pediatric and adult cardiology care constitute a particularly vulnerable population, as beta-blocker adherence frequently deteriorates during this period [103].

Electrolyte management forms a cornerstone of preventive care. Serum potassium should be maintained in the high-normal range through dietary supplementation or potassium-sparing diuretics, as elevated extracellular potassium enhances Kv11.1 conductance and partially compensates for channel dysfunction [102,104]. However, recent clinical data have challenged the long-term prophylactic value of potassium elevation in normokalemic patients. The TriQarr study demonstrated that moderate plasma potassium elevation failed to provide sustained antiarrhythmic benefit, suggesting that routine potassium supplementation may not be warranted in LQTS patients maintaining normal electrolyte levels [105]. Magnesium supplementation provides additional benefit by stabilizing cardiac membranes, with guideline recommendations supporting its use in TdP management [106]. Patient education should emphasize maintaining adequate hydration and promptly correcting electrolyte disturbances during intercurrent illnesses.

Lifestyle modifications tailored to genotype-specific triggers substantially reduce arrhythmic events. LQTS2 patients should receive counseling regarding auditory trigger avoidance: utilizing vibrating alarm clocks, maintaining phones on vibrate mode, and ensuring household members wake patients gently [89]. While swimming carries particular risk in LQTS1, it appears less problematic in LQTS2, though supervision remains advisable. Female patients planning pregnancy require preconception counseling regarding elevated postpartum risk and should undergo enhanced monitoring extending through at least six months post-delivery [87].

Genetic counseling provides essential information regarding inheritance patterns, reproductive options including preimplantation genetic diagnosis, and cascade screening protocols, with contemporary guidance provided by the 2022 EHRA/HRS/APHRS/LAHRS expert consensus statement [80]. Approximately 50% of offspring carry the pathogenic variant, necessitating evaluation of all first-degree relatives. Identifying mutation-negative family members enables discontinuation of unnecessary restrictions, while mutation-positive but phenotype-negative individuals require ongoing surveillance and risk factor modification [106].

4.4. Therapeutic Decision-Making

Beta-adrenergic receptor antagonists constitute first-line pharmacological therapy for LQTS2, demonstrating significant cardiac event reduction across multiple cohort studies [107,108]. Comparative effectiveness data reveal important differences among agents: nadolol and propranolol demonstrate superior efficacy compared to metoprolol, possibly reflecting their longer half-lives and non-selective β-receptor blockade [109,110]. Nadolol, dosed to achieve resting heart rates of 50–60 bpm (typical adult range: 40–240 mg daily in one or two divided doses), provides optimal protection.

Beta-blocker initiation decisions balance individual risk stratification against potential adverse effects. Consensus guidelines recommend therapy in all symptomatic LQTS2 patients, males with QTc > 470 ms, females with QTc > 480 ms, and asymptomatic genotype-positive individuals with QTc > 500 ms [74]. For asymptomatic patients with borderline QT prolongation, shared decision-making incorporating patient preferences, trigger exposure, and family history guides therapeutic choices. Breakthrough cardiac events despite beta-blocker therapy occur in a substantial minority of LQTS2 patients, with rates varying by beta-blocker selection [110], necessitating consideration of additional interventions (as outlined in Figure 2).

Implantable cardioverter-defibrillator (ICD) implantation provides definitive protection against sudden cardiac death but carries significant implications, such as inappropriate shocks, infection risk, lead complications, and psychological burden, particularly in young patients requiring decades of device-dependent care [111,112]. Current guidelines recommend ICD implantation for secondary prevention in cardiac arrest survivors and primary prevention in patients experiencing recurrent syncope despite beta-blocker therapy [74]. Shared decision-making incorporating detailed discussion of risks, benefits, device longevity, and lifestyle implications remains essential. Left cardiac sympathetic denervation (LCSD) provides an alternative intervention for high-risk patients experiencing breakthrough events despite optimal medical therapy [113]. This procedure, involving resection of the lower left stellate ganglion and thoracic ganglia T2–T4, demonstrates effectiveness with approximately 90% of patients remaining event-free post-procedure. Combining LCSD with beta-blocker therapy and, when indicated, ICD implantation provides maximal protection in highest-risk individuals.

Emerging pharmacological strategies targeting Kv11.1 dysfunction show promise but require clinical validation. Channel activators represent a novel therapeutic class addressing LQTS2 pathophysiology directly. LUF7244, a selective allosteric modulator, enhances I_Kr current by inhibiting channel inactivation without affecting I_Ks, I_Na, or I_CaL [65,114]. Preclinical studies demonstrated effective suppression of dofetilide-induced early afterdepolarizations and TdP prevention in chronic atrioventricular block models, despite incomplete QTc normalization [65]. These findings suggest partial I_Kr enhancement may provide sufficient antiarrhythmic protection. However, concerns regarding overcorrection and paradoxical pro-arrhythmia at higher concentrations necessitate careful dose optimization [64]. Predictive models incorporating dynamic channel–drug binding kinetics may facilitate identification of activators with optimal therapeutic windows [57].

Pharmacological chaperones represent a promising mutation-specific strategy for trafficking-deficient LQTS2 variants. Lumacaftor, originally developed for cystic fibrosis, rescues membrane trafficking of specific KCNH2 mutations including G604S, N633S, and R685P, in iPSC-derived cardiomyocytes [71]. However, clinical translation requires careful consideration of mutation-specific effects. In KCNH2-G604S carriers, lumacaftor paradoxically prolonged APD90, likely through enhanced trafficking of mutant channels exerting dominant-negative effects on wild-type subunits [71]. This observation underscores the necessity for mutation-specific functional characterization before implementing chaperone therapy. Additionally, splice site mutations such as IVS9-2delA, which shift expression from functional Kv11.1a to nonfunctional Kv11.1a-USO isoform, are not amenable to trafficking correction [70], highlighting the need for alternative therapeutic strategies in these patients.

Gene therapy approaches offer potential for definitive KCNH2 mutation correction. Suppression and replacement strategies employ dual mechanisms: silencing defective alleles using RNA interference or antisense oligonucleotides, combined with insertion of silencing-resistant wild-type sequences [115]. Preclinical studies in iPSC-derived cardiomyocytes have demonstrated successful I_Kr restoration and action potential normalization using AAV-mediated delivery [115]. CRISPR-Cas9 gene editing enables precise mutation-specific correction in both LQTS2 and Brugada syndrome [116]. While these technologies remain investigational, advances in cardiac-specific delivery vectors and editing efficiency suggest potential clinical translation within the coming decade.

For Brugada syndrome related to KCNH2 gain-of-function mutations, therapeutic approaches differ substantially from LQTS2 management. Beta-blockers provide no benefit and may worsen outcomes. ICD implantation remains the only proven therapy for preventing sudden cardiac death, recommended for cardiac arrest survivors or those experiencing syncope attributable to ventricular arrhythmias [117]. Quinidine, an I_Kr blocker, demonstrates antiarrhythmic efficacy by counteracting increased potassium current, representing a rare scenario where Kv11.1 blockade provides therapeutic benefit [118]. Beyond pharmacological management, the arrhythmogenic substrate in BrS is frequently localized to the epicardial surface of the right ventricular outflow tract (RVOT), where areas of prolonged, fragmented electrograms reflect the abnormal depolarization that underlies the characteristic ECG pattern and vulnerability to ventricular fibrillation [119]. In patients with high-risk phenotypes, including those experiencing recurrent VF episodes or electrical storms with repeated ICD therapies, epicardial catheter ablation targeting this substrate has emerged as an established interventional strategy. Substrate elimination, typically guided by sodium channel blocker challenge to unmask the full extent of the arrhythmogenic area, has been shown to normalize the BrS ECG pattern, render VF non-inducible, and significantly reduce arrhythmic recurrences [120]. A recent randomized trial confirmed that epicardial ablation substantially reduced VF recurrence compared with ICD therapy alone in high-risk patients [121]. Importantly, epicardial ablation is regarded as complementary to, rather than a replacement for, ICD protection, and its role continues to be refined as longer-term follow-up data become available [119].

Pregnancy management in LQTS2 requires coordinated multidisciplinary care. Beta-blocker therapy should continue throughout pregnancy, as arrhythmic risk substantially exceeds medication risks [87]. The postpartum period represents the highest-risk interval, with nearly 50% of pregnancy-associated events occurring during the first nine months post-delivery [87]. Enhanced monitoring, beta-blocker continuation, electrolyte optimization, and stress reduction during this vulnerable period reduce event rates. Epidural anesthesia represents the preferred approach for labor, as certain inhalational general anesthetics may prolong QT intervals [122].

4.5. Special Populations and Emerging Considerations

Pediatric LQTS2 patients present unique management challenges: ECG interpretation difficulties in neonates, beta-blocker adherence issues, and sudden infant death syndrome (SIDS) concerns in affected infants [123,124]. Approximately 10% of SIDS cases demonstrate postmortem genetic evidence of cardiac channelopathies, including KCNH2 mutations. Molecular autopsy in SIDS cases with suggestive clinical or family histories enables identification of at-risk relatives requiring surveillance [125].

Competitive athletes with LQTS2 face difficult decisions regarding sports participation, as adrenergic stimulation, emotional stress, and dehydration may trigger arrhythmias. Guidelines recommend competitive sports restriction for symptomatic patients and asymptomatic individuals with QTc > 500 ms [73,126]. For athletes with borderline QT prolongation or genotype-positive but phenotype-negative status, individualized shared decision-making guides participation decisions. Continued participation requires mandatory beta-blocker therapy, dehydration avoidance, emergency action planning, and automated external defibrillator access [127].

Elderly patients with Kv11.1 channelopathies present distinct challenges related to polypharmacy, reduced drug clearance, increased QT prolongation susceptibility, and comorbidities requiring Kv11.1-blocking medications [95]. Comprehensive medication review with QT-prolonging agent discontinuation when feasible, preferential selection of alternatives lacking Kv11.1 effects, and enhanced pharmacokinetic monitoring reduce iatrogenic risk. Age-related renal function decline necessitates dose adjustments for renally cleared Kv11.1 blockers including sotalol and dofetilide [128,129].

5. Conclusions

Kv11.1 channels are crucial regulators of cardiac repolarization and rhythmicity, playing a vital role in maintaining the heart’s electrical stability. Dysfunction of Kv11.1 channels, whether caused by genetic mutations or drug interactions, is a major contributor to arrhythmogenic conditions such as LQTS, BS, and TdP. Beyond their well-established role in cardiac function, Kv11.1 channels have also been implicated in non-cardiac physiological and pathological processes, including cardiomyocyte proliferation, pulmonary hypertension, and, notably, cancer progression.

Advances in structural biology and molecular pharmacology have revealed detailed insights into the complex regulatory mechanisms of Kv11.1, laying the foundation for targeted therapeutic strategies. These include channel activators, blockers, and trafficking correctors tailored for precision treatment. However, the heterogeneity of Kv11.1 mutations and their context-dependent functional effects present significant challenges in translating these therapies across diverse conditions.

From a clinical perspective, the integration of molecular understanding with practical management algorithms enables personalized care for patients with Kv11.1 channelopathies. Systematic risk stratification using electrocardiographic parameters, genetic testing, and family history assessment identifies high-risk individuals requiring intensive intervention, while recognizing lower-risk patients who may be managed with lifestyle modifications and surveillance alone. Beta-blocker therapy remains the cornerstone of LQTS2 management, demonstrating consistent efficacy in reducing cardiac events when combined with trigger avoidance and electrolyte optimization. For patients with drug-induced QT prolongation, rigorous pre-prescription screening, drug interaction assessment, and post-initiation monitoring minimize iatrogenic arrhythmic risk. The availability of advanced interventions including ICD implantation and left cardiac sympathetic denervation provides additional protection for the highest-risk individuals experiencing breakthrough events despite optimal medical therapy.

Future research utilizing high-throughput drug screening, precision medicine, and advanced computational modeling will be essential for refining Kv11.1-targeted approaches. The development of mutation-specific pharmacological chaperones, allosteric modulators with reduced overcorrection risk, and gene therapy strategies holds promise for transforming LQTS2 from a lifelong condition requiring multiple interventions into a potentially correctable disorder. Equally important, continued efforts to identify novel Kv11.1 channel blockers early in drug development, implement comprehensive drug safety surveillance programs, and educate healthcare providers regarding QT-prolonging medication risks will reduce the burden of acquired channelopathies. This integrated strategy, combining molecular insights with evidence-based clinical decision-making, offers the potential not only to improve outcomes for patients with arrhythmic disorders but also to broaden the therapeutic applications of Kv11.1 modulation to diseases such as cancer and other systemic conditions.